ANTEOTECH LTD — Capital/Financing Update 2013

Dec 15, 2013

==> picture [209 x 115] intentionally omitted <==

16[th] December 2013 Company Announcements Office Australian Securities Exchange Limited Level 6, 20 Bridge Street Sydney NSW 2000

ANTEO COMPLETES $5.5 MILLION PLACEMENT

• 44 million new shares to be issued to a range of institutional and professional investors

• Placement done at 12.5 cents per share – 19% discount to the last trade

• Funds to be used to bring forward the commercialisation of two patent applications

• Anteo well-funded for growth with $8million cash at bank and growing revenue streams

16 December 2013: Anteo Diagnostics Limited (ASX:ADO) is pleased to report that it has completed a $5.5 million placement at 12.5 cents per share to a number of institutional and private investors. A total of 44 million new Fully Paid Ordinary Shares will be issued (pursuant to the Company’s 15% capacity under ASX Listing Rule 7.1) which will rank equally with the Ordinary Shares currently on issue. The placement was oversubscribed and done at a 19% discount to the last trade of 15.5 cents per share. Bell Potter Securities acted as Lead Manager for this placement.

Following this capital raising, Anteo is well funded with total cash at bank of approximately $8 million. These funds provide the company with the financial flexibility to expedite the development and commercialisation of products, made possible by the filing of two new patents, which complement the existing Mix&Go product portfolio from 7 years to 3 years. These new patents will expand the protected areas of application to bioseparations, drug screening, drug delivery and areas outside the health care industry and the funds bring revenues from these areas much closer.

Anteo’s Managing Director and Chief Executive Officer, Dr Geoff Cumming commented: “Anteo has received considerable support for this capital raising and we are delighted to welcome a number of new investors, including a number of institutional investors, to the company’s register. The support given to this placement is a further endorsement of our growth strategy and the potential of the Mix & Go technology. We would like to thank investors for their support and welcome them as shareholders in the Company.

“Anteo has been very active since signing the Heads of Terms with BBI. Our team has been heavily engaged on a number of fronts. The scientific group now has an agreed Project Plan and work on its execution is well underway. We expect to be able to transfer some material to BBI early in the New Year that will allow collaborative work to commence. The scientific team has also made sound progress on other projects. Our business development team attended the Medica conference in Germany

Anteo Diagnostics Limited ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

advancing the state of play with several customers and engaging with some new companies. Further, they have continued the work of getting third party beta-testing underway for our Streptavidin Bead and Plate Products. Finally the corporate group has completed this placement. We now head into Christmas well-placed for future growth and we look forward to updating shareholders on our progress throughout the next quarter.”

ENDS

For further information please contact:

Dr Geoff Cumming, Managing Director & CEO Anteo Diagnostics Limited Tel: +61 2 8823 3110

Jane Morgan Six Degrees Investor Relations Tel: +61 405 555 618 jane.morgan@sdir.com.au

About Anteo: Anteo Diagnostics Limited (ASX:ADO) (“Anteo”) is an Australian biotechnology company that develops, manufactures and commercialises proprietary surface coatings for the global healthcare industry. Anteo’s patented technology is Mix&Go[TM ] – a “molecular glue” used in life sciences, pathology tests and point-of-care diagnostics to help identify and detect diseases more reliably and earlier.

Anteo Diagnostics Limited ABN 78 090 487 273 Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113 Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com